Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Racial differences in waiting list placement improved in states that expanded Medicaid.
Requiring sobriety prior to treatment and curtailing harm reduction hinder efforts to eliminate hep C.
Some state Medicaid programs and prison systems still restrict treatment based on substance use or stage of liver disease.
The move was lauded by the National Viral Hepatitis Roundtable and a health law program at Harvard Law School.
Adults with chronic liver disease are more than twice as likely than those without the condition to have barriers to medical care.
37 state Medicaid programs continue to restrict access to lifesaving medication—despite medical guidelines telling them not to.
Many Medicaid systems do.
The state would pay a fixed annual amount for an unlimited supply of HCV drugs for its Medicaid program.
The Trump administration had proposed changing which meds were covered, including HIV and cancer drugs.
The proposal rolls back nondiscrimination policies of the Affordable Care Act, notably for transgender people and women who had abortions.
Insurance companies can no longer implement harmful co-pay accumulator policies.
A look at the supply chain that results in very high costs for HIV and hepatitis C medications.
The subscription-based model is the first of its kind.
Nearly 21 million Americans could lose coverage. Meanwhile, the GOP won’t offer a health care replacement until after 2020.
In fact, antiviral drugs account for nearly 14 percent of total drug costs in the program.
The patient advocacy coalition I Am Essential sent a letter to the HHS spelling out why the plan is dangerous.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.